Timothy R Sterling1, Ruth N Moro2, Andrey S Borisov3, Elizabeth Phillips4, Gillian Shepherd5, Newton Franklin Adkinson6, Stephen Weis7, Christine Ho3, Margarita Elsa Villarino3. 1. Vanderbilt University School of Medicine, Nashville, Tennessee. 2. Centers for Disease Control and Prevention CDC Foundation, Research Collaboration, Atlanta, Georgia. 3. Centers for Disease Control and Prevention. 4. Vanderbilt University School of Medicine, Nashville, Tennessee Institute for Immunology and Infectious Diseases, Murdoch University, Perth, Australia. 5. New York-Presbyterian Hospital/Weill Cornell Medical Center, New York. 6. Johns Hopkins University School of Medicine, Baltimore, Maryland. 7. University of North Texas Health Science Center at Ft. Worth.
Abstract
BACKGROUND: Weekly rifapentine plus isoniazid for 3 months (3HP) is as effective as daily isoniazid for 9 months (9H) for latent tuberculosis infection in high-risk persons, but there have been reports of possible flu-like syndrome. METHODS: We identified clinically significant systemic drug reactions (SDR) and evaluated risk factors in patients who did not complete treatment in the PREVENT Tuberculosis study. RESULTS: Among 7552 persons who received ≥ 1 dose of study drug, 153 had a SDR: 138/3893 (3.5%) with3HP vs 15/3659 (0.4%) with 9H (P < .001). In the 3HP arm, 87 (63%) had flu-like syndrome and 23 (17%) had cutaneous reactions; 13/3893 (0.3%) had severe reactions (6 were hypotensive) and 6 reported syncope. Symptoms occurred after a median of 3 doses, and 4 hours after the dose; median time to resolution was 24 hours. There were no deaths. In multivariate logistic regression analysis, factors independently associated with SDR included receipt of 3HP (adjusted odds ratio [aOR] 9.4; 95% confidence interval [CI], 5.5, 16.2), white non-Hispanic race/ethnicity (aOR 3.3; 95% CI, 2.3, 4.7), female sex (aOR 2.0; 95% CI, 1.4, 2.9), age ≥ 35 years (aOR 2.0; 95% CI, 1.4, 2.9), and lower body mass index (body mass index [BMI]; P = .009). In a separate multivariate analysis among persons who received 3HP, severe SDR were associated with white non-Hispanic race/ethnicity (aOR 5.4; 95% CI, 1.8, 16.3), and receipt of concomitant non-study medications (aOR 5.9; 95% CI, 1.3, 27.1). CONCLUSIONS: SDR were more common with 3HP, and mostly flu-like. Persons of white race, female sex, older age, and lower BMI were at increased risk. Severe reactions were rare and associated with 3HP, concomitant medication, and white race. The underlying mechanism is unclear. CLINICAL TRIALS REGISTRATION: NCT00023452. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
RCT Entities:
BACKGROUND: Weekly rifapentine plus isoniazid for 3 months (3HP) is as effective as daily isoniazid for 9 months (9H) for latent tuberculosis infection in high-risk persons, but there have been reports of possible flu-like syndrome. METHODS: We identified clinically significant systemic drug reactions (SDR) and evaluated risk factors in patients who did not complete treatment in the PREVENT Tuberculosis study. RESULTS: Among 7552 persons who received ≥ 1 dose of study drug, 153 had a SDR: 138/3893 (3.5%) with 3HP vs 15/3659 (0.4%) with 9H (P < .001). In the 3HP arm, 87 (63%) had flu-like syndrome and 23 (17%) had cutaneous reactions; 13/3893 (0.3%) had severe reactions (6 were hypotensive) and 6 reported syncope. Symptoms occurred after a median of 3 doses, and 4 hours after the dose; median time to resolution was 24 hours. There were no deaths. In multivariate logistic regression analysis, factors independently associated with SDR included receipt of 3HP (adjusted odds ratio [aOR] 9.4; 95% confidence interval [CI], 5.5, 16.2), white non-Hispanic race/ethnicity (aOR 3.3; 95% CI, 2.3, 4.7), female sex (aOR 2.0; 95% CI, 1.4, 2.9), age ≥ 35 years (aOR 2.0; 95% CI, 1.4, 2.9), and lower body mass index (body mass index [BMI]; P = .009). In a separate multivariate analysis among persons who received 3HP, severe SDR were associated with white non-Hispanic race/ethnicity (aOR 5.4; 95% CI, 1.8, 16.3), and receipt of concomitant non-study medications (aOR 5.9; 95% CI, 1.3, 27.1). CONCLUSIONS: SDR were more common with 3HP, and mostly flu-like. Persons of white race, female sex, older age, and lower BMI were at increased risk. Severe reactions were rare and associated with 3HP, concomitant medication, and white race. The underlying mechanism is unclear. CLINICAL TRIALS REGISTRATION: NCT00023452. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
adverse drug reaction; flu-like syndrome; isoniazid; rifapentine; treatment of latent M. tuberculosis infection
Authors: Jens U Rüggeberg; Michael S Gold; José-Maria Bayas; Michael D Blum; Jan Bonhoeffer; Sheila Friedlander; Glacus de Souza Brito; Ulrich Heininger; Babatunde Imoukhuede; Ali Khamesipour; Michel Erlewyn-Lajeunesse; Susana Martin; Mika Mäkelä; Patricia Nell; Vitali Pool; Nick Simpson Journal: Vaccine Date: 2007-03-12 Impact factor: 3.641
Authors: Naomi N Bock; Timothy R Sterling; Carol D Hamilton; Connie Pachucki; Yong-Cheng Wang; Donna S Conwell; Ann Mosher; Mary Samuels; Andrew Vernon Journal: Am J Respir Crit Care Med Date: 2002-06-01 Impact factor: 21.405
Authors: Mauro Schechter; Roberto Zajdenverg; Gisely Falco; Grace Link Barnes; José Cláudio Faulhaber; Jacqueline S Coberly; Richard D Moore; Richard E Chaisson Journal: Am J Respir Crit Care Med Date: 2006-02-10 Impact factor: 21.405
Authors: Timothy R Sterling; Nigel A Scott; Jose M Miro; Guilherme Calvet; Alberto La Rosa; Rosa Infante; Michael P Chen; Debra A Benator; Fred Gordin; Constance A Benson; Richard E Chaisson; M Elsa Villarino Journal: AIDS Date: 2016-06-19 Impact factor: 4.177
Authors: Gibril J Njie; Sapna Bamrah Morris; Rachel Yelk Woodruff; Ruth N Moro; Andrew A Vernon; Andrey S Borisov Journal: Am J Prev Med Date: 2018-06-14 Impact factor: 5.043
Authors: Susan Swindells; Ritesh Ramchandani; Amita Gupta; Constance A Benson; Jorge Leon-Cruz; Noluthando Mwelase; Marc A Jean Juste; Javier R Lama; Javier Valencia; Ayotunde Omoz-Oarhe; Khuanchai Supparatpinyo; Gaerolwe Masheto; Lerato Mohapi; Rodrigo O da Silva Escada; Sajeeda Mawlana; Peter Banda; Patrice Severe; James Hakim; Cecilia Kanyama; Deborah Langat; Laura Moran; Janet Andersen; Courtney V Fletcher; Eric Nuermberger; Richard E Chaisson Journal: N Engl J Med Date: 2019-03-14 Impact factor: 91.245
Authors: Robert Belknap; David Holland; Pei-Jean Feng; Joan-Pau Millet; Joan A Caylà; Neil A Martinson; Alicia Wright; Michael P Chen; Ruth N Moro; Nigel A Scott; Bert Arevalo; José M Miró; Margarita E Villarino; Marc Weiner; Andrey S Borisov Journal: Ann Intern Med Date: 2017-11-07 Impact factor: 25.391
Authors: Kristina M Brooks; Jomy M George; Alice K Pau; Adam Rupert; Carolina Mehaffy; Prithwiraj De; Karen M Dobos; Anela Kellogg; Mary McLaughlin; Maryellen McManus; Raul M Alfaro; Colleen Hadigan; Joseph A Kovacs; Parag Kumar Journal: Clin Infect Dis Date: 2018-07-02 Impact factor: 9.079
Authors: Kendra K Radtke; Jacqueline P Ernest; Nan Zhang; Nicole C Ammerman; Eric Nuermberger; Robert Belknap; Rosanna Boyd; Timothy R Sterling; Rada M Savic Journal: Antimicrob Agents Chemother Date: 2021-10-04 Impact factor: 5.191